LOXO Oncology Revenue and Competitors
Estimated Revenue & Valuation
- LOXO Oncology's estimated annual revenue is currently $159M per year.
- LOXO Oncology received $294.8M in venture funding in June 2017.
- LOXO Oncology's estimated revenue per employee is $281,400
- LOXO Oncology's total funding is $506M.
Employee Data
- LOXO Oncology has 565 Employees.
- LOXO Oncology grew their employee count by 37% last year.
LOXO Oncology Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.5M | 67 | 116% | N/A | N/A |
#2 | $907.7M | 4516 | 11% | N/A | N/A |
#3 | $7.6M | 38 | 0% | N/A | N/A |
#4 | $10501.6M | 52247 | 6% | N/A | N/A |
#5 | $84.2M | 419 | 98% | N/A | N/A |
#6 | $3.2M | 39 | 26% | N/A | N/A |
#7 | $28.9M | 144 | 19% | N/A | N/A |
#8 | $38M | 189 | 6% | N/A | N/A |
#9 | $3.2M | 39 | 56% | N/A | N/A |
#10 | $12.3M | 61 | -12% | N/A | N/A |
What Is LOXO Oncology?
Loxo Oncology is a biopharmaceutical company dedicated to developing highly-selective medicines for patients with genomically defined cancers. Our pipeline is focused on treatments aimed at cancers caused by a single inappropriate DNA change, known as oncogenic drivers, which the tumor depends on for growth and survival. Loxo Oncology develops purpose-built medicines designed to selectively and potently inhibit these oncogenic drivers. We believe that this approach, combined with the use of tumor genomic testing to identify appropriate patients, will allow us to develop medicines that provide best-in-class disease control and safety and, ultimately, deliver on the promise of precision medicine. We are based in Stamford, CT with sites in San Francisco, CA and Boulder, CO. For more information about Loxo Oncology, please visit us at www.loxooncology.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$506M
Total Funding
565
Number of Employees
$159M
Revenue (est)
37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
LOXO Oncology News
Jake Van Naarden - Chief Executive Officer, Loxo Oncology, Lilly and President, Lilly Oncology. Mike Mason - President, Lilly Diabetes.
... testing services and global oncology contract research services, ... Biomarkers and Diagnostics Development, Loxo Oncology at Lilly.
... had undergone treatment with pirtobrutinib (LOXO-305; Eli Lilly, Loxo Oncology), a noncovalent Bruton tyrosine kinase (BTK) inhibitor.
INDIANAPOLIS, Oct. 7, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that preclinical characterization data for two new agents, LOXO-783 and LOXO-435, will be presented at the 2021 AACR-NCI-EORTC Virtual Interna ...
One example is the drug Vitrakvi, developed by Eli Lilly and its Loxo Oncology, which is marketed by Bayer. Vitrakvi works on cancers where ...
Other Companies in Stamford
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $195.3M | 625 | -5% | N/A |
#2 | $175.7M | 639 | -18% | N/A |
#3 | $169.8M | 647 | N/A | N/A |
#4 | $226.8M | 672 | N/A | N/A |
#5 | $251M | 702 | -1% | $1.5M |
LOXO Oncology Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-05-07 | $24.0M | B | New Enterprise Associates | Article |
| 2017-06-22 | $294.8M | Undisclosed | Morgan Stanley | Article |
